Invasive aspergillosis in organ transplant recipients: new issues in epidemiologic characteristics, diagnosis, and management

References

• Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999; 78: 123–138
   PubMed Web of Science ®Google Scholar
• Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplantation 2004; 4: 636–643
   PubMed Web of Science ®Google Scholar
• Kwak EJ, Husain S, Obman A, et al. Efficacy of galactomannan antigen using Platelia® Aspergillus enzyme immunoassay for the diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42: 435–438
   PubMed Web of Science ®Google Scholar
• Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia™ Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4: 796–802
   PubMed Web of Science ®Google Scholar
• Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46–52
   PubMed Web of Science ®Google Scholar
• Lugardon K, Chasserot-Golaz S, Kieffer A-E, et al. Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide. J Biol Chem 2001; 276: 35875–35882
   PubMed Web of Science ®Google Scholar
• High KP. The antimicrobial activities of cyclosporine, FK506, and rapamycin. Transplantation 1994; 57: 1689–1700
   PubMed Web of Science ®Google Scholar
• Steinbach, WJ, Singh, N, Miller, JL, , et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and non-transplant patients. Antimicrob Agents Chemother 2004, (in press).
   Google Scholar
• Murase N, Metes D, Zeevi A, et al. Immunomonitoring of liver transplant recipients treated with tolerance-enhancing regimen of immunosuppression. Am J Transplant 2004; 8: 40
   Google Scholar
• Koffron JCC, Dixler I, Kulik L, et al. Campath 1-H (alemtuzumab) induction in liver transplantation: a single center experience. Am J Transplant 2004; 8: 267
   Google Scholar
• Shapiro R, Tan HP, Basu A, et al. Campath 1-H preconditioning and tacrolimus monotherapy with subsequent weaning in renal transplant recipients. Am J Transplant 2004; 8: 405
   Google Scholar
• Almyroudis, S, Jaffe, D, Sepkowitz, KA, , et al. Risk factors for late invasive aspergillosis (IA) after allogeneic stem cell transplantation. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14–17, 2003.
   Google Scholar
• Stynen D, Goris A, Sarfati J, Latge JP. A new sensitive sandwich ELISA to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497–500
   PubMed Web of Science ®Google Scholar
• Maertens JJ, Verhaegan J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillsois. J Clin Microbiol 1999; 37: 3223–3228
   PubMed Web of Science ®Google Scholar
• Verweij PE, Stynen D, Rijs AMMM, et al. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 1995; 33: 1912–1914
   PubMed Web of Science ®Google Scholar
• Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Ped Infect Dis J 1996; 15: 232–237
   PubMed Web of Science ®Google Scholar
• Bretagne S, Costa J-M, Bart-Delabesse E, et al. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998; 26: 1407–1412
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610
   PubMed Web of Science ®Google Scholar
• Machetti M, Feasi M, Mordini N, et al. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant 1998; 21: 917–921
   PubMed Web of Science ®Google Scholar
• Ulusakarya A, Chachaty E, Vantelon J-M, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1: 111–116
   PubMedGoogle Scholar
• Fortun J, Martin-Davila P, Alvarez ME, et al. The Ramon y Cajal Hospital's liver Transplant Group. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001; 71: 145–149
   PubMed Web of Science ®Google Scholar
• Cameron ML, Granger DL, Matthews TJ, Weinberg JB. Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. J Infect Dis 1994; 170: 60–70
   Google Scholar
• Linden PK. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin Pharmacother 2003; 4: 2099–2110
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Eng J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Hachem, RY, Raad, II, Afif, CM, , et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy. 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, TorontoCanada, September 17–20, 2000.
   Google Scholar
• Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003; 51: 313–316
   PubMed Web of Science ®Google Scholar
• Fox DS, Heitman J. Good fungi gone bad: the corruption of calcineurin. BioEssays 2003; 24: 894–903
   Google Scholar